In a report released today, Yi Chen from H.C. Wainwright reiterated a Buy rating on Check-Cap (CHEK – Research Report), with a price target of $7.00. The company’s shares opened today at $1.34.
Chen covers the Healthcare sector, focusing on stocks such as Prophase Labs, CareDx, and Applied DNA Sciences. According to TipRanks, Chen has an average return of -25.8% and a 25.51% success rate on recommended stocks.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Check-Cap with a $7.00 average price target.
See the top stocks recommended by analysts >>
The company has a one-year high of $9.18 and a one-year low of $1.22. Currently, Check-Cap has an average volume of 64.23K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Check-Cap Ltd. is a clinical stage medical diagnostics company, which engages in developing gastrointestinal imaging devices. It develops capsule-based system that utilizes low-dose X-rays to detect polyps, masses and colorectal cancer screening. The company was founded by Yoav Kimchy in 2005 and is headquartered in Isfiya, Israel.
Read More on CHEK:
